c-Jun N-terminal Kinase 1 ablation protects against metabolic-induced hippocampal cognitive impairments
MetadataShow full item record
Abstract: The development of metabolic alterations like insulin resistance has been associated with dysfunctions in mitochondrial oxidative capacity, induction of neuroinflammatory responses, and the appearance of cognitive impairments in the brain. The c-Jun N-terminal Kinase 1 (JNK1) is a potential key modulator of these mechanisms. The current study identifies a protective effect of whole-body JNK1 knockout in the presence of a high-fat diet (HFD). Specifically, the data suggest that mice missing JNK1 show increased insulin sensitivity and mitochondrial activity, as well as reduced body weight, and astrocyte and microglial reactivity. Finally, these animals are also protected against HFD-induced cognitive impairments as assessed through novel object recognition test, the observation of dendritic spines, and the levels of BDNF or other proteins like spinophilin and ARC. Thus, modulation of JNK1 activity seems like a promising approach for the design of therapies aimed at treating metabolic-induced cognitive impairments. Key messages: JNK1 is a link between obesity/type 2 diabetes and cognitive lossInhibition of JNK1 is neuroprotectiveJNK1 constitutes a therapeutic strategy for cognitive loss. © 2019, Springer-Verlag GmbH Germany, part of Springer Nature.
Showing items related by title, author, creator and subject.
ReviewBusquets O.; Ettcheto M.; Cano A.; Manzine P.R.; Sánchez-Lopez E.; Espinosa-Jiménez T.; Verdaguer E.; Castro-Torres R.D.; Beas-Zarate C.; Sureda F.X.; ... (MDPI AG, 2020)
Role of brain c-Jun N-terminal kinase 2 in the control of the insulin receptor and its relationship with cognitive performance in a high-fat diet pre-clinical model (2020) Busquets O.; Eritja À.; López B.M.; Ettcheto M.; Manzine P.R.; Castro-Torres R.D.; Verdaguer E.; Olloquequi J.; Vázquez-Carrera M.; Auladell C.; ... (Blackwell Publishing Ltd, 2019)
Environmental enrichment reverses tyrosine kinase inhibitor-mediated impairment through BDNF-TrkB pathway (2020) Bengoetxea H.; Rico-Barrio I.; Ortuzar N.; Murueta-Goyena A.; Lafuente J.V. (Humana Press Inc., 2018)